Ad26-CV

adenovirus (Ad26) viral vector COVID-19 vaccine

AEFI

adverse event following immunisation

AFP

acute flaccid paralysis

AIDS

acquired immunodeficiency syndrome

AIR

Aotearoa Immunisation Register

AOM

acute otitis media

BCG

bacillus Calmette–Guérin vaccine

CARM

Centre for Adverse Reactions Monitoring

CDC

Centers for Disease Control and Prevention

ChAd-CV

adenovirus (ChAdOx1) viral vector COVID-19 vaccine

CHD

congenital heart disease

COVID-19

coronavirus disease 2019

CPR

cardiopulmonary resuscitation

CRS

congenital rubella syndrome

cVDPV

circulating vaccine-derived polio virus

CVWUS

COVID-19 vaccinators working under supervision

DNA

deoxyribonucleic acid

DT

diphtheria tetanus vaccine

DTaP

diphtheria, tetanus and acellular pertussis vaccine

DTaP-IPV

diphtheria, tetanus, acellular pertussis and inactivated polio vaccine

DTaP-IPV-HepB/Hib

diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B and Haemophilus influenzae type b vaccine

DTwP

diphtheria, tetanus and whole-cell pertussis vaccine

DTwPH

diphtheria, tetanus, whole-cell pertussis and Haemophilus influenzae type b vaccine

ESR

Institute of Environmental Science and Research

GBS

Guillain–Barré syndrome

GP

general practitioner

GSK

Formerly GlaxoSmithKline (New Zealand)

HAV

hepatitis A virus

HBcAg

hepatitis B core antigen

HBeAg

hepatitis B e antigen

HBIG

hepatitis B immunoglobulin

HBsAg

hepatitis B surface antigen

HBV

hepatitis B virus

HepA

hepatitis A vaccine

HepB

hepatitis B vaccine

Hib

Haemophilus influenzae type b

Hib-PRP

Haemophilus influenzae type b polyribosylribitol phosphate vaccine conjugated with tetanus toxoid

HIV

human immunodeficiency virus

HPV

human papillomavirus

HSCT

haematopoietic stem cell transplant

ICD

International Classification of Diseases

IFNAR

interferon alpha receptor

IG

immunoglobulin

IgG

immunoglobulin G

IM

intramuscular

IMAC

Immunisation Advisory Centre

IMID

immune-mediated inflammatory disease

IPD

invasive pneumococcal disease

IPV

inactivated polio vaccine

ISRR

immunisation stress-related response

irAE

immunisation-related adverse events

ITP

idiopathic thrombocytopenic purpura (also known as immune thrombocytopenia)

IV

intravenous

IVIG

intravenous immunoglobulin

LAIV

live attenuated influenza vaccine

Medsafe

New Zealand Medicines and Medical Devices Safety Authority

MenACWY

quadrivalent meningococcal conjugate vaccine

MenB

Four-component recombinant meningococcal B vaccine

MenB-fHbp

Two component recombinant meningococcal B vaccine

MenC

meningococcal C conjugate vaccine

MeNZB

New Zealand epidemic meningococcal B vaccine

MMR

measles, mumps and rubella vaccine

MMRV

measles, mumps, rubella and varicella vaccine

mRNA

messenger ribonucleic acid

mRNA-CV

messenger RNA COVID-19 vaccine

MSD

Merck Sharp & Dohme (New Zealand)

NHI

National Health Index

NIP

National Immunisation Programme

NIR

National Immunisation Register

NTHi

non-typeable Haemophilus influenzae

NZBS

New Zealand Blood Service

OPV

oral polio vaccine

PAV

provisional authorised vaccinator

PCR

polymerase chain reaction

PCV7

7-valent pneumococcal conjugate vaccine

PCV10

10-valent pneumococcal conjugate vaccine

PCV13

13-valent pneumococcal conjugate vaccine

23PPV

23-valent pneumococcal polysaccharide vaccine

PFU

plaque-forming unit

PHARMAC

Pharmaceutical Management Agency

PIMS-TS

paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2

PMS

practice management system (also known as patient management system)

PPE

personal protective equipment

PRP

polyribosylribitol phosphate

PSNZ

Pharmaceutical Society of New Zealand

PTAC

Pharmacology and Therapeutics Advisory Committee

QIV

quadrivalent influenza vaccine

RIG

rabies immunoglobulin

RNA

ribonucleic acid

rCV

recombinant spike protein COVID-19 vaccine, adjuvanted

RSV

respiratory syncytial virus

RSVpreF

respiratory syncytial virus prefusion F protein vaccine

RV1

rotavirus vaccine (monovalent)

RV5

rotavirus vaccine (pentavalent)

rZV

recombinant zoster vaccine, adjuvanted

SARS-CoV-2

serious acute respiratory syndrome coronavirus 2

SBVS

school-based vaccination system

SC

subcutaneous

SCID

severe combined immune deficiency

STI

sexually transmitted infection

SUDI

sudden unexpected death in infancy

TB

tuberculosis

Td

adult tetanus and diphtheria vaccine (formerly ADT-Booster)

Tdap

adult tetanus, diphtheria and acellular pertussis vaccine

TIG

tetanus immunoglobulin

TIV

trivalent influenza vaccine

UK

United Kingdom

US

United States of America

VAERS

vaccine adverse event reporting system (US)

VAPP

vaccine-associated paralytic poliomyelitis

VFC

vaccinator foundation course

VHW

vaccinating health workers

VLP

virus-like particle

VV

varicella vaccine

VZV

varicella zoster virus

WHO

World Health Organization

ZIG

zoster immunoglobulin

ZV

zoster vaccine